Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14).

Hundemer, M; Klein, U; Hose, D; Raab, M-S; Cremer, F W; Jauch, A; Benner, A; Heiss, C; Moos, M; Ho, A D; Goldschmidt, H

Hundemer, M; Klein, U; Hose, D; Raab, M-S; Cremer, F W; Jauch, A; Benner, A; Heiss, C; Moos, M; Ho, A D; Goldschmidt, H.

Affiliation

Hundemer M; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

Bone Marrow Transplant ; 40(11): 1033-7, 2007 Dec.

Article in En | MEDLINE | ID: mdl-17891186

Subject(s)

CD56 Antigen/metabolism; Melphalan/administration & dosage; Multiple Myeloma/drug therapy; Multiple Myeloma/genetics; Myeloablative Agonists/administration & dosage; Adult; Aged; Biomarkers; CD56 Antigen/genetics; Chromosomes, Human, Pair 11/genetics; Chromosomes, Human, Pair 17/genetics; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma/pathology; Retrospective Studies; Translocation, Genetic/genetics; Transplantation, Autologous

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: CD56 Antigen / Myeloablative Agonists / Melphalan / Multiple Myeloma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2007 Type: Article

Search on Google

XML

PubMed Links